EX-1 2 ff2392491_13da17-ex1.htm
JOINT FILING AGREEMENT
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D and any amendments to it with respect to Common Stock, $0.001 par value per share, of Mirati Therapeutics, Inc. and further agree that this Joint Filing Agreement be included as an Exhibit to those joint filings. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.

Dated: August 15, 2023
  BOXER CAPITAL, LLC  
       

By:
/s/ Aaron I. Davis  
  Name: Aaron I. Davis  
  Title: Chief Executive Officer  
       
       
  BOXER ASSET MANAGEMENT INC.  
       
 
By:
/s/ Paul Higgs
 
  Name: Paul Higgs
 
  Title: Director  
       
       
  BRASLYN LTD.
 
       
 
By:
/s/ Jason Callender  
  Name: Jason Callender  
  Title: Director  
       
   
 
  MVA INVESTORS, LLC  
       
 
By:
/s/ Aaron I. Davis  
  Name: Aaron I. Davis  
  Title: Authorized Signatory  
       
       
  LOCKEND FIVE, LLC  
       
 
By:
/s/ Greg Miller  
  Name: Greg Miller  
  Title: Manager  
       
       
  JOSEPH C. LEWIS  
       
 
By:
/s/ Joseph C. Lewis
 
 
Joseph C. Lewis, Individually  
       
       
  AARON I. DAVIS  
       
 
By:
/s/ Aaron I. Davis
 
 
Aaron I. Davis, Individually  





  SHEHAN B. DISSANAYAKE  
       
 
By:
/s/ Shehan B. Dissanayake  
    Shehan B. Dissanayake, Individually  
       
       
  CHRISTOPHER FUGLESANG  
       
 
By:
/s/ Christopher Fuglesang
 
    Christopher Fuglesang, Individually